Compare Stocks

→ Pentagon contract could send this $2 AI stock soaring (From Behind the Markets) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CHEK Check-Cap	$2.22 -3.1%	$2.25	$1.27 ▼ $4.63	$12.99M	0.28	210,926 shs	25,020 shs
NSCI Nanalysis Scientific	C$0.45 -1.1%	C$0.43	C$0.35 ▼ C$0.66	C$50.08M	0.82	65,969 shs	110,700 shs
XBIO Xenetic Biosciences	$3.85	$4.08	$2.55 ▼ $5.97	$5.93M	2.6	7,203 shs	537 shs

The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CHEK Check-Cap	+0.88%	+2.23%	+13.37%	+5.53%	+63.57%
NSCI Nanalysis Scientific	+7.14%	+26.76%	+13.92%	+13.92%	-30.77%
XBIO Xenetic Biosciences	+1.85%	-4.11%	-0.26%	+17.74%	-12.02%

Pentagon contract could send this $2 AI stock soaring (Ad)

Whenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...

Get all the info here >>>

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CHEK Check-Cap	0.3052 of 5 stars	0.0	2.0	0.0	0.0	3.2	0.0	1.3
NSCI Nanalysis Scientific	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
XBIO Xenetic Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CHEK Check-Cap	2.00	Hold	N/A	N/A
NSCI Nanalysis Scientific	N/A	N/A	N/A	N/A
XBIO Xenetic Biosciences	2.00	Hold	N/A	N/A

Current Analyst Ratings

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CHEK Check-Cap	N/A	N/A	N/A	N/A	$8.57 per share	N/A
NSCI Nanalysis Scientific	C$25.87M	1.94	C$0.05 per share	8.93	C$0.25 per share	1.78
XBIO Xenetic Biosciences	$2.54M	2.33	N/A	N/A	$6.36 per share	0.61

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CHEK Check-Cap	-$19.11M	-$3.02	N/A	N/A	N/A	N/A	-47.85%	-43.50%	5/9/2024 (Estimated)
NSCI Nanalysis Scientific	-C$16.96M	-C$0.17	N/A	∞	N/A	-65.57%	-47.87%	-15.68%	4/25/2024 (Estimated)
XBIO Xenetic Biosciences	-$4.14M	-$2.75	N/A	N/A	N/A	-162.84%	-36.43%	-33.74%	5/9/2024 (Estimated)

Latest CHEK, XBIO, and NSCI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/21/2024	Q4 2023	XBIO Xenetic Biosciences	-$0.87	-$0.77	+$0.10	-$0.77	$0.68 million	$0.67 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CHEK Check-Cap	N/A	N/A	N/A	N/A	N/A
NSCI Nanalysis Scientific	N/A	N/A	N/A	N/A	N/A
XBIO Xenetic Biosciences	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CHEK Check-Cap	N/A	17.60	17.60
NSCI Nanalysis Scientific	71.36	1.52	1.11
XBIO Xenetic Biosciences	N/A	11.84	11.84

Ownership

Institutional Ownership

Company	Institutional Ownership
CHEK Check-Cap	1.07%
NSCI Nanalysis Scientific	0.03%
XBIO Xenetic Biosciences	15.12%

Insider Ownership

Company	Insider Ownership
CHEK Check-Cap	0.48%
NSCI Nanalysis Scientific	7.11%
XBIO Xenetic Biosciences	9.00%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
CHEK Check-Cap	85	5.85 million	5.82 million	Not Optionable
NSCI Nanalysis Scientific	249	112.54 million	N/A	Not Optionable
XBIO Xenetic Biosciences	4	1.54 million	1.40 million	Not Optionable

CHEK, XBIO, and NSCI Headlines

Source	Headline
	Xenetic Biosciences Inc (XBIO) investing.com - April 10 at 3:28 PM
	Xenetic Biosciences Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag finance.yahoo.com - March 24 at 5:09 PM
	Xenetic Dips on Full-Year Results baystreet.ca - March 22 at 7:33 PM
	Xenetic Biosciences reports FY results msn.com - March 22 at 8:51 AM
	Xenetic Biosciences, Inc. Reports Full Year 2023 Financial Results accesswire.com - March 22 at 8:00 AM
	Xenetic to advance DNase programme with UVA partnership msn.com - January 18 at 1:37 PM
	Xenetic Biosciences Inc XBIO morningstar.com - January 4 at 5:10 PM
	Xenetic Biosciences Stock (NASDAQ:XBIO), Guidance and Forecast benzinga.com - December 11 at 9:01 AM
	Most Shareholders Will Probably Agree With Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation finance.yahoo.com - November 30 at 10:39 AM
	Xenetic Biosciences: Q3 Earnings Insights benzinga.com - November 10 at 3:38 PM
	MediciNova: Q3 Earnings Snapshot washingtonpost.com - November 10 at 10:37 AM
	Xenetic Biosciences, Inc. to Participate at the Virtual Investor Ask the CEO Conference finance.yahoo.com - October 11 at 9:30 AM
	Xenetic Biosciences (XBIO) Upgraded to Strong Buy: What Does It Mean for the Stock? msn.com - July 13 at 1:44 PM
	Xenetic Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update finance.yahoo.com - May 11 at 5:06 PM
	Xenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison \| Morningstar morningstar.com - May 5 at 10:21 AM
	Xenetic Biosciences, Inc. Bolsters R&D and Regulatory Expertise with Appointment of Reid P. Bissonnette, Ph.D. as Executive Consultant for Translational Research and Development finance.yahoo.com - May 4 at 10:02 AM
	Xenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison finance.yahoo.com - May 3 at 10:26 AM
	HC Wainwright & Co. Reiterates Xenetic Biosciences (XBIO) Buy Recommendation msn.com - April 12 at 10:37 PM
	Xenetic Biosciences forms research collaboration with TSRI pharmaceutical-technology.com - April 12 at 12:36 PM
	Analysts Offer Insights on Healthcare Companies: Adaptimmune Therapeutics (ADAP) and Xenetic Biosciences (XBIO) markets.businessinsider.com - April 12 at 2:30 AM
	Xenetic Biosciences, Inc. Announces Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform finance.yahoo.com - April 11 at 8:43 AM
	JTC Team, LLC: JTC Team to Host Virtual Investor NETs in Cancer Spotlight Event Featuring Xenetic Biosciences finanznachrichten.de - March 16 at 12:09 PM
	JTC Team to Host Virtual Investor NETs in Cancer Spotlight Event Featuring Xenetic Biosciences finance.yahoo.com - March 16 at 12:09 PM
	XBIO Xenetic Biosciences, Inc. seekingalpha.com - February 23 at 11:29 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Check-Cap

NASDAQ:CHEK

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. Check-Cap Ltd. was incorporated in 2004 and is based in Isfiya, Israel.

Nanalysis Scientific

CVE:NSCI

Nanalysis Scientific Corp. engages in the development, manufacture, and sale of magnetic resonance products in the United States, Canada, Europe, Asia, and internationally. The company operates through four segments: Nanalysis, RS2D, K'Prime, and Corporate. It offers nuclear magnetic resonance (NMR) spectrometers; software module packages; cutting-edge electronics components for precision analytical instruments; and services for its NMR technologies. It serves pharmaceutical, security, biotech, nutraceutical, chemical, food, materials, medical, and education industries. The company is headquartered in Calgary, Canada.

Xenetic Biosciences

NASDAQ:XBIO

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial